Published 13 days ago • loading... • Updated 12 days ago

Novo Nordisk, Seen as Lagging in Obesity Drug Race, Says It’s Playing the Long Game

Summary by STAT

Executives argue coming readouts on next-generation candidates such as CagriSema and amycretin and overall strategy will pay off.

4 Articles

All

Left

Center

Right

The Motley Fool

Lean Left

Why Shares in Novo Nordisk Lost Weight Today @themotleyfool #stocks $NVO

12 days ago·Alexandria, United States

Read Full Article

STAT

Center

Novo Nordisk, seen as lagging in obesity drug race, says it’s playing the long game

Executives argue coming readouts on next-generation candidates such as CagriSema and amycretin and overall strategy will pay off.

12 days ago·Boston, United States

Read Full Article

Capital.de

Novo Nordisk and Co.: Health Shares in Difficult Waterways

Not long ago, Novo Nordisk was the most valuable stock exchange company in Europe. However, the share price of the manufacturer of weight loss syringes has fallen. Also in 2025, it is not running around with other healthcare companiesThe healthcare sector is considered a high-margin growth segment of the economy. However, this judgment did not prevent many shares from this sector from producing little positive advances at the last. The viewer im…

13 days ago

Read Full Article

ib.dk

They Need to Find Novo's New CEO - InsideBusiness

Headhunter Heidrick & Struggles has secured what must probably be described as the most prestigious search assignment in Denmark. The firm will thus find a replacement for the fired Novo Nordisk CEO Lars Fruergaard, who was sacrificed in mid-May by its owner, the Novo Nordisk Foundation, and its powerful chairman and predecessor as CEO, Lars Rebien Sørensen. Fruergaard's exit came after a long period of share price decline and a few unusual setb…

13 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year